Cognitive Health Interventions for Schizophrenia
(iCogCA Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to effectively implement virtually-delivered interventions in mental health institutions nationwide to improve the cognitive health of individuals living with schizophrenia. The main objectives are: * To determine the clinical effectiveness of two virtual cognitive health interventions (i.e., Action-Based Cognitive Remediation or MetaCognitive Training). * To evaluate our implementation strategy involving the virtual delivery of cognitive health interventions combined with a digital learning platform to train mental health practitioners. Participants will be assessed for the severity of symptoms, cognitive performance, and overall functioning before and after receiving the intervention. Qualitative interviews will also be conducted with participants and therapists to evaluate the implementation strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Cognitive remediation, Cognitive Remediation Therapy, Cognitive Training, Cognitive Rehabilitation, MetaCognitive Training, MetaCognitive Training, MCT for schizophrenia?
Research shows that cognitive remediation and metacognitive training can help improve thinking skills and social functioning in people with schizophrenia. These treatments have been found to reduce cognitive deficits and improve real-world outcomes, making them promising strategies for early intervention in schizophrenia.12345
Is metacognitive training (MCT) safe for people with schizophrenia?
How is the treatment Cognitive Health Interventions for Schizophrenia different from other treatments for this condition?
Cognitive Health Interventions for Schizophrenia, including Cognitive Remediation and MetaCognitive Training, are unique because they focus on improving cognitive and social functioning through psychological therapy rather than medication. These treatments use computer-based exercises and group training to enhance thinking skills and correct cognitive biases, aiming to improve daily living and reduce symptoms like delusions.2391011
Research Team
Martin Lepage, PhD
Principal Investigator
Douglas Mental Health University Institute
Eligibility Criteria
This trial is for individuals with schizophrenia or related disorders who are stable and can use online platforms. They must have a private space for sessions, an emergency contact, and be able to communicate in English or French. Those with intellectual disabilities, high suicide risk, or current hospitalization cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive virtual cognitive health interventions (Action-Based Cognitive Remediation or MetaCognitive Training) over a period of 8-12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of symptomatology, cognitive performance, and overall functioning
Treatment Details
Interventions
- Cognitive remediation (Behavioral Intervention)
- MetaCognitive Training (Behavioral Intervention)
Cognitive remediation is already approved in Canada for the following indications:
- Schizophrenia
- Cognitive Impairment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Douglas Mental Health University Institute
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Dr. Paul C. Hébert
Canadian Institutes of Health Research (CIHR)
Chief Executive Officer
MD, University of Ottawa
Dr. Paul C. Hébert
Canadian Institutes of Health Research (CIHR)
Chief Medical Officer
MD, University of Ottawa
McGill University
Collaborator
Philippe Drouet
McGill University
Chief Executive Officer since 2021
Master of Science and Bachelor in Chemical Engineering from McGill University
Marianne Mancini
McGill University
Chief Medical Officer
BS in Nutritional Sciences from McGill University